Skip to main content
OpenTrials
Completed

NCT Number: NCT03597139

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Aurinia Investigative Center, Garden Grove, California, United States

Loading trial locations.

About this study

This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a best corrected visual acuity (BCVA) in both eyes of +0.7 logarithm of the Minimum Angle of Resolution (logMAR) or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.
  • Have a documented history of DED in both eyes supported by a previous clinical diagnosis.
  • Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting all the following criteria:
  • A symptom severity score of ≥30 for Eye Dryness on a Visual Analog Scale (VAS) (0-100)
  • An unanesthetized Schirmer Tear Test (STT) score of ≥1 mm and ≤10 mm per 5 minutes (Note: STT Score obtained at Visit 1)
  • Evidence of ocular surface staining (total fluorescein staining score of at least 3 [0-15 scale]).
  • Have normal lid anatomy.

Exclusion criteria

  • Have any known hypersensitivity or contraindication to study treatments (including excipients), topical anesthetics or vital dyes.
  • Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular lubricant.
  • Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit 2 (based on score of ≥30 on the Drop Discomfort VAS).
  • Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit 1.
  • Have used Restasis® for more than 1 month (if prior use is reported).
  • Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior to Visit 1.
  • Have had corneal graft surgery in either eye within 1 year.
  • Have recent or current evidence of ocular infection or inflammation in either eye.
  • Have current evidence of clinically significant blepharitis (defined as requiring lid hygiene therapy), conjunctivitis, or a history of herpes simplex or zoster keratitis in either eye.

Treatment and study plan

Voclosporin Ophthalmic Solution

Drug

Investigational Drug

Other names: 0.2% VOS

Restasis®

Drug

Comparator

Other names: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%

Primary outcomes

  1. Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1

    Time frame: 1-minute Post Dose 1 installation (Day 1)

    Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

Secondary outcomes

  1. Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28

    Time frame: Day 28

    Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

  2. Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28

    Time frame: Day 28

    Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging".

  3. Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28

    Time frame: 28 days

    Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation".

  4. Change From Baseline in Photophobia Post Dose Instillation on Day 28

    Time frame: 28 days

    Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia".

  5. Change From Baseline in Eye Pain Post Dose Instillation on Day 28

    Time frame: 28 days

    Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain".

  6. Change From Baseline in Eye Dryness Post Dose Instillation on Day 28

    Time frame: 28 days

    Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness".

  7. Change From Baseline in Itching Post Dose Instillation on Day 28

    Time frame: 28 days

    Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching".

  8. Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores

    Time frame: Day 28

    The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).

  9. Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)

    Time frame: Day 28

    The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.

  10. Change From Baseline in Unanesthetized Schirmer Test Score

    Time frame: 28 days

    The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is <5mm of wetting on the test strip.

  11. Change From Baseline in Fluorescein Corneal Staining (FCS) Score

    Time frame: 28 days

    The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.

Sponsors and collaborators

Lead sponsor

Aurinia Pharmaceuticals Inc.

Industry

Registry information

Official study title

An Investigator-Masked, Randomized, Parallel-Group Study of the Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jul 24, 2018
Registry last updated
Jul 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.